INTRODUCTION
============

Impulsivity, the tendency to act prematurely without foresight, represents a core feature of several neuropsychiatric disorders (eg, attention-deficit/hyperactivity disorder (ADHD), mania and substance abuse) ([@bib16]; [@bib31]). The catecholamines dopamine (DA) and norepinephrine (NE) are widely implicated in the modulation of impulsivity through the clinical efficacy of drugs that increase brain DA and NE function (eg, methylphenidate (MPH) and atomoxetine (ATO)) and by evidence that DA-ergic and NE-ergic transmission are deficient in patients with impulse control disorders ([@bib15]; [@bib22]).

Animal studies support a role for DA and NE in impulsivity. Thus, depletion of DA in the ventral striatum of rats, including the nucleus accumbens (NAcb), has the profound effect of reducing impulsivity on a five-choice serial reaction time task (5-CSRTT) ([@bib14]) similar to the effects of DA receptor antagonists infused locally into the NAcb core (NAcbC) ([@bib36]; [@bib39]). Drugs that increase brain DA neurotransmission (eg, amphetamine and MPH) produce divergent effects on impulsive behavior, generally acting to improve stopping performance on stop-signal reaction time tasks and reducing delay-discounting impulsivity while increasing 5-CSRTT impulsivity ([@bib21]; [@bib23]; [@bib33]). Enhancing extracellular NE levels by systemic treatment with the selective NE re-uptake transporter (NET) inhibitor ATO decreases several distinct forms of impulsivity in rats ([@bib43]). However, the precise neural mechanisms underlying the regulation of impulsivity by NE and DA are not yet clear and could involve both cortical (eg, prefrontal cortex, PFC) and subcortical regions, especially the NAcbC and NAcb shell (NAcbS) ([@bib18], [@bib16]).

Data from both animals and humans converge to suggest that PFC-striatal circuitry is an important substrate for the manifestation of pathologically impulsive behavior ([@bib18]; [@bib40]). Indeed, optimal levels of DA and NE are critical to PFC function and suboptimal transmission can lead to PFC dysfunction and symptoms resembling ADHD ([@bib2]; [@bib3]). Although the NAcb receives a dense dopaminergic innervation from the ventral tegmental area ([@bib28]; [@bib48]), only the NAcbS receives a significant input from locus ceruleus and the medullary A2 group of NE neurons ([@bib7]; [@bib19]; [@bib29]). However, the functional importance of this afferent NE-ergic innervation of the NAcbS in impulsivity is unknown.

Here, we investigated the effects on impulsivity of the selective NET inhibitor ATO and the mixed DAT/NET inhibitor MPH ([@bib24]; [@bib50]) infused directly into either the NAcbC or NAcbS, or the prelimbic (Prl) and infralimbic (IL) cortex. Impulsivity was defined as the number of premature responses on the 5-CSRTT, an attentional paradigm requiring action restraint during a waiting interval for a reward-predictive target stimulus ([@bib41]). To rule out nonspecific effects, we also investigated the effects of intra-PFC and intra-NAcb infusions of ATO and MPH on spontaneous locomotor activity.

MATERIALS AND METHODS
=====================

Animals
-------

Outbred male Lister Hooded rats (Charles River, Margate, UK) weighing 280--300 g at the beginning of the experiments were used. Water was available *ad libitum* and food was given at the end of each day\'s testing. Rats were housed under temperature and humidity controlled conditions and a reversed 12-h light--dark cycle (lights off at 0700 hours). All procedures conformed to the UK (1986) Animal (Scientific Procedures) Act (Project license 80/2234).

5-CSRTT
-------

A detailed description of the apparatus and procedures employed has been described previously ([@bib4]). A PC using WhiskerServer software and FiveChoice client controlled the apparatus ([@bib10]). Briefly, subjects were trained on the 5-CSRTT to detect the location of a brief visual stimulus (0.5 s) presented pseudo-randomly in one of five spatially distinct apertures on the front wall of the chamber. Each session consisted of 100 discrete trials and lasted approximately 30 min. Trials were initiated by animals entering the food magazine on the opposite wall, and after an intertrial interval (ITI) of 5 s had elapsed, the visual stimulus was presented in a single location that varied on a trial-by-trial basis. Rats were rewarded with a food pellet (Noyes dustless pellets, Research Diets, UK) if they correctly located the position of the target stimulus with a nose-poke response; deemed a 'correct\' response. A failure to respond within 5 s of the target presentation resulted in a time-out (TO) period of 5 s and was deemed an 'omission\'. Responses made before the target stimulus or in an adjacent hole were deemed 'premature\' or 'incorrect\' responses, respectively, and also resulted in TO. Responses during TO were not further punished. Responses made in any hole after a correct or incorrect response but before collecting the food pellet were deemed 'perseverative\' responses and were never punished. Performance was assessed using seven variables: premature responses; choice accuracy (% correct/correct+incorrect responses); omissions (% omissions/correct+incorrect+omissions); perseverative responses; latency to make a correct or an incorrect response after the onset of the target stimulus (ms); and, latency to collect food from the magazine after a correct trial (ms).

Following stable baseline performance on the 5-CSRTT (ITI=5 s), drug testing begun. As the main dependent variable in our studies was the number of premature responses, on drug treatment days we increased the inter-trial interval to 7 s to avoid potential floor effects. We have found that imposing a fixed long ITI (LoITI) significantly increases the frequency of premature responses ([@bib17]) and thus widens the window for detecting decreases as well as increases in impulsive behavior. Before drug testing began, animals experienced three LoITI sessions spaced at weekly intervals to generate a stable baseline level of heightened impulsivity.

Locomotor Activity
------------------

Locomotor activity was evaluate in 12 chambers (Med Associates; 29.5 × 32.5 × 23.5 cm) equipped with infrared photocell beams and controlled by a PC. The day before initiation of drug testing, animals were habituated to the locomotor chambers for 2 h. On drug treatment days, animals were initially placed into the locomotor chambers for 30 min (habituation). Animals were then removed from the chambers, given the respective drug/vehicle infusion and returned to the chambers 5 min later. Locomotor activity was then recorded for a further 30 min and was measured as photocell beam interruptions. Drug testing was conducted every third day.

Drugs
-----

ATO hydrochloride (a gift from Eli Lilly, Basingstoke, UK) was dissolved in 0.01 mol/l phosphate-buffered saline (PBS). MPH hydrochloride (Sigma, Cambridge, UK) was dissolved in 0.9% sterile saline. Both drugs were given by intracranial infusions (0.5 μl per infusion).

Intracranial Surgery
--------------------

Rats were anesthetized with ketamine hydrochloride (100 mg/kg; Ketaset, Fort Dodge Animal Health, Southampton, UK) and xylazine (9 mg/kg; Rompun, Bayer, Newbury, Germany), and secured in a stereotaxic frame with the incisor bar set at −3.3 mm relative to the interaural line in flat skull position. Bilateral 22-gauge double guide cannulae (Plastics One, Sevenoaks, UK) were implanted bilaterally in the cortex overlying the medial (m)PFC (PrL/IL), NAcbC, or the NacbS, according to published stereotaxic coordinates ([Table 1](#tbl1){ref-type="table"}; [@bib37]). Cannulae were secured to the skull with dental acrylic and stainless steel screws and occluded by a stylet. After surgery animals were allowed to recover for 1 week.

Intracranial Microinfusions
---------------------------

Drug infusions were given 5 min before behavioral testing. Animals were habituated to the infusion procedure over two daily sessions and received on both occasions a single vehicle infusion over 1 min (ATO; PBS, MPH; saline, 0.5 μl). During this procedure, rats were gently restrained by the experimenter while the obturators were removed from the cannulae and the respective bilateral injectors lowered into the intended brain region. Following each infusion, the injector remained in the brain for 2 min. The injector was then removed and the obturator replaced before placing the animal into the respective test apparatus.

Histological Assessment
-----------------------

At completion of the experiments, rats were killed by an overdose of sodium pentobarbital (1.5 ml per rat, Dolethal 200 mg/ml, Rhone-Merieux, Athens), and perfused transcardially with 0.01 M PBS followed by 4% paraformaldehyde. The brains were removed, post-fixed in 4% paraformaldehyde, and transferred to 20% sucrose solution in 0.01 M PBS overnight before being sectioned into 60 μm coronal sections. Every third section was mounted and stained with Cresyl Violet. Cannulae placements were verified under light microscope and mapped onto standardized coronal sections of the rat brain ([@bib37]).

Experiment 1: Effects of Intra-NAcbS Infusions of ATO or MPH on 5-CSRTT Performance
-----------------------------------------------------------------------------------

Two groups of rats with bilateral cannulae aimed at the NAcbS (*n*=7--8 per group) were infused with either ATO or MPH (0.5--5.0 μg), or their respective vehicle (see above) before 5-CSRTT testing. Infusions were given according to a Latin square design and were delivered at 0.5 μl per site over 1 min. Before the drug treatment day, rats were run daily on the 5-CSRTT with a reduced ITI of 5 s. One week after the last drug infusion animals received a vehicle infusion (ATO or MPH vehicle, respectively) and were re-tested with a LoITI session. Following histological assessment, three animals from the ATO group and two animals from the MPH group were excluded from further analysis.

Experiment 2: Effects of Intra-NAcbC Infusions of ATO or MPH on 5-CSRTT Performance
-----------------------------------------------------------------------------------

Two groups of rats (*n*=9 per group), were implanted with guide cannulae above the NAcbC. One group of rats received intra-NAcbC infusions of ATO (0.0, 1.5, or 5.0 μg); the second group received intra-NAcbC MPH (0.0--5.0 μg). Following termination of drug treatments, animals received a vehicle NAcbC infusion and were tested on a control LoITI session (see, experiment 1). Following histological assessment, cannulae were misplaced in one animal from the MPH group and therefore was excluded from further analysis.

Experiment 3: Effects of Intra-PrL and Intra-IL Infusions of ATO or MPH on 5-CSRTT Performance
----------------------------------------------------------------------------------------------

Two groups of rats (*n*=10 per group) were implanted with guide cannulae overlying the mPFC. The first group received intra-PrL infusions of ATO (0.0--5.0 μg) and following a 1-week washout period, the same rats received infusions of ATO into the IL. A second group of rats received infusions of MPH (0.0--5.0 μg) into first the PrL and latter into the IL after a 1-week washout. Both sets of rats (ATO and MPH) received the respective vehicle infusion 1 week after the last drug infusion and were tested under a LoITI. Following histological assessment, two animals from each group (ATO and PMH) were excluded from further analysis.

Experiment 4: Effects of Intra-NAcbS and NAcbC Infusions of ATO and MPH on Locomotor Activity
---------------------------------------------------------------------------------------------

The effects of ATO and MPH (0.0 and 5.0 μg) on locomotor activity were investigated in two groups of rats with bilateral cannulae above the NAcbS (*n*=14) or the NAcbC (*n*=10). Animals destined for NAcbS infusions were divided in two subgroups (*n*=7 per group) with similar levels of baseline locomotor activity during habituation. The first subgroup of rats received, in a counterbalanced manner, intra-NAcbS infusions of ATO (0.0 or 5.0 μg), whereas the second subgroup received MPH (0.0 or 5.0 μg). Subsequently, the drug treatment was reversed. Thus, the first subgroup now received MPH (0.0 or 5.0 μg), whereas the second subgroup now received ATO (0.0 or 5.0 μg). Animals destined for NAcbC infusions were divided in two subgroups (*n*=5 per group), and were tested for locomotor activity following ATO and/or MPH treatment as described above. Following histological assessment, misplaced cannulae were found in five NAcbS animals and in two NAcbC operated animals. These animals were excluded from further analysis.

Experiment 5: Effects of Intra-PrL and Intra-IL Infusions of ATO and MPH on Locomotor Activity
----------------------------------------------------------------------------------------------

Rats (*n*=12) with bilateral cannulae aimed at the PrL received, in a counterbalanced order, 5.0 μg ATO or its vehicle. Following a 1-week washout, the same rats received ATO or vehicle infusions into the IL in a counterbalanced order. A second group of rats (*n*=10) received MPH (0.0 or 5.0 μg), into both the PrL and IL, as described above. The histological assessment identified four animals from the ATO group and two animals from the MPH group with misplaced cannulae. These animals were excluded from further analysis.

Statistical Analysis
--------------------

The results are presented as means (±SEM) for each behavioral variable (5-CSRTT: premature responses, choice accuracy, omissions, perseverative responses, latency to make a correct or an incorrect response and latency to collect food reward; locomotor activity: photocell beam interruptions). Behavioral data were analyzed using repeated-measures analysis of variance (ANOVA) with dose as a within-subjects factor (SPSS, Chicago, IL). *Post-hoc* Newman--Keuls comparisons were used where appropriate. Statistical significance was set at *p*\<0.05.

RESULTS
=======

Histology
---------

[Figure 1](#fig1){ref-type="fig"} shows the most central location of the infusion cannulae tips in the NAcbS and NAcbC and in the PrL and IL. Following the histological assessment, animals in which the cannulae were positioned outside the target areas were excluded from the study. The final group sizes for each experiment are shown in [Table 2](#tbl2){ref-type="table"}.

Experiment 1: Effects of Intra-NAcbS Infusions of ATO or MPH on 5-CSRTT Performance
-----------------------------------------------------------------------------------

Intra-NAcbS infusions of ATO resulted in a significant decrease in the number of premature responses (F~(3, 12)~=7.2, *p*\<0.01) ([Figure 2a](#fig2){ref-type="fig"}). *Post-hoc* tests revealed a significant decrease in premature responding after treatment with all doses of ATO. ATO did not significantly affect attentional accuracy, omissions, the latency to make a correct response, or the latency to collect food reward (all *p-*values=NS) ([Table 3](#tbl3){ref-type="table"}). During the final control LoITI session, there was a significant increase in the number of premature responses compared with the baseline response (ie, measured during a 5 s ITI) but not compared with the vehicle-treated groups, suggesting that there was no habituation in premature responding during the experiment ([Figure 2a](#fig2){ref-type="fig"}).

In contrast, intra-NAcbS MPH infusions had no significant effect on premature responding (F~(3, 12)~=0.8, *p*=NS) ([Figure 2c](#fig2){ref-type="fig"}), attentional accuracy, omissions, or the latency to collect food from the magazine (all *p-*values=NS) ([Table 3](#tbl3){ref-type="table"}). However, MPH (1.5 μg) did reduce the latency to make a correct response (*p*\<0.05) ([Table 3](#tbl3){ref-type="table"}). A similar pattern of effects was observed during the final control LoITI session to that described for ATO above ([Figure 2c](#fig2){ref-type="fig"}).

Experiment 2: Effects of Intra-NAcbC Infusions of ATO or MPH on 5-CSRTT Performance
-----------------------------------------------------------------------------------

Intra-NAcbC ATO infusions had no effect on premature responding (F~(2, 16)~=0.5, *p*=NS) ([Figure 2b](#fig2){ref-type="fig"}), or any other behavioral variables (all *p-*values=NS) ([Table 3](#tbl3){ref-type="table"}). By contrast, intra-NAcbC infusions of MPH resulted in a marked increase in premature responding (F~(3, 21)~=6.7, *p*\<0.01), which was significant at the 5.0 μg dose (*p*\<0.01) ([Figure 2d](#fig2){ref-type="fig"}). This response was highly selective with no additional effects on any other behavioral variable (all *p-*values=NS) ([Table 3](#tbl3){ref-type="table"}).

Experiment 3: Effects of Intra-PrL and Intra- IL Infusions of ATO or MPH on 5-CSRTT Performance
-----------------------------------------------------------------------------------------------

Intra-PrL infusions of ATO had no significant effect on premature responding (F~(2, 14)~=1.9, *p*=NS) ([Figure 3a](#fig3){ref-type="fig"}), or any other variables on the 5-CSRTT (all *p-*values=NS) ([Table 4](#tbl4){ref-type="table"}). Intra-IL ATO also had no significant effect on premature responding (F~(2, 10)~=0.1, *p*=NS) ([Figure 3b](#fig3){ref-type="fig"}), or any other behavioral variables (all *p-*values=NS) ([Table 4](#tbl4){ref-type="table"}). A similar profile of effects was observed following infusions of MPH in the PrL and IL with no significant effects (*p*=NS) on any of the behavioral measures except a significant decrease in omissions following intra-IL treatment (*p*\<0.05) at the dose of 5.0 μg ([Figures 3c--d](#fig3){ref-type="fig"}, [Table 4](#tbl4){ref-type="table"}).

Experiment 4: Effects of Intra-NAcbS and NAcbC Infusions of ATO and MPH on Locomotor Activity
---------------------------------------------------------------------------------------------

Locomotor activity was not significantly affected by either intra-NAcbS or intra-NAcbC ATO infusions. By contrast, locomotor activity was significantly increased following both intra-NAcbS and intra-NAcbC infusions of MPH (*p*\<0.001) ([Figures 4a--b](#fig4){ref-type="fig"}).

Experiment 5: Effects of Intra-PrL and Intra-IL Infusions of ATO and MPH on Locomotor Activity
----------------------------------------------------------------------------------------------

Intra-PrL ATO infusions did not significantly affect locomotor activity. However, when infused in the IL, ATO resulted in a significant decrease in locomotor activity (*p*\<0.01) ([Figure 4a](#fig4){ref-type="fig"}). MPH did not alter locomotion when infused in the PrL or IL cortex ([Figure 4b](#fig4){ref-type="fig"}).

DISCUSSION
==========

The results of these experiments show that the NAcb is a key area for regulating the expression of impulsive behavior, assessed by premature responding on the 5-CSRTT, which is critically and oppositely modulated by NE-ergic and DA-ergic mechanisms in the shell and core sub-regions of the NAcb. There was a reduction in impulsivity following intra-NAcbS, but not intra-NAcbC infusion of the selective NET inhibitor ATO. In contrast, intra-NAcbC, but not intra-NAcbS infusions of the mixed NET/DAT inhibitor MPH resulted in the opposite effect and significantly increased premature responding. Neither of these drugs altered impulsivity on the 5-CSRTT following intra-PrL or intra-IL administration. In a separate experiment, intra-NAcbC MPH, while producing high levels of premature responding, also elicited locomotor hyperactivity. However, although to a lesser extent, increased locomotor activity was also found following intra-NAcbS infusions of MPH, which was an ineffective site for inducing premature or impulsive responding in the 5-CSRTT. Locomotor activity was not altered by MPH when infused into the PrL and IL cortex. In contrast, although ATO had no significant effect on locomotor behavior when infused into any of the NAcb sub-regions, it did result in a decrease when infused into the IL. The reported effects were unlikely to be mediated by sites distal to the microinjection location because (i) ATO produced strongly divergent effects on behavior when injected into the closely flanking core and shell sub-regions of the NAcb, and (ii) dissociable behavioral effects were observed after infusions of ATO into the PFC and NAcb.

The premature or anticipatory index of responding in the 5-CSRTT is considered a valid measure of a key construct of impulsivity, namely 'waiting impulsivity\', which depends critically on the integrity of the NAcbC ([@bib11]; [@bib16]). However, the neurochemical mechanisms that modulate this NAcb control over the ability to anticipate signals predictive of reward, wait for them, and respond on the onset of a stimulus have not been defined. The NAcb is a heterogeneous structure with two anatomically and functionally distinct compartments, the core and shell ([@bib27]). A major distinction between these sub-territories is related to their NE-ergic innervation, which predominantly targets the shell, with inputs primarily originating in the medullary A2 NE-ergic cell group of the nucleus tractus solitarius ([@bib7]; [@bib19]; [@bib29]). This is of particular interest in light of our results showing opponent modulation of impulsivity by ATO and MPH in the NAcbS and NAcbC. Thus, intra-NAcbS infusions of ATO resulted in a marked reduction in impulsivity of a magnitude similar to the effects of systemically administering ATO ([@bib35]; [@bib43]). This effect is likely attributable to NET blockade and increased NE transmission in the NAcbS. Conversely, the increased impulsivity seen following local intra-NAcbC infusions of the mixed DAT/NET inhibitor MPH can instead be attributed to DAT blockade and increased DA transmission in the NacbC given a scarce local NE innervation ([@bib7]; [@bib19]; [@bib29]) and the absence of any trend of effect following direct ATO infusion. By contrast, in the NAcbS, the lack of effect of MPH on impulsivity could be attributed to its dual inhibitory effect on DAT and NET ([@bib24]). Of particular interest in this context are anatomical data demonstrating reciprocal connections between the shell and the core ([@bib20]; [@bib27]) and microdialysis data suggesting a functional interaction between these two areas indicating a prominent role of the NE system in modulating DA release within the NAcb ([@bib30]; [@bib47]). Therefore, we hypothesize that the NAcbS, via its NE-ergic innervation, acts to regulate extracellular DA levels in the NAcbC and thereby determines the level of inhibitory control over a prepotent response ([@bib16]; [@bib26]).

In support of this hypothesis, intra-NAcbC infusions of DA receptor agonists and antagonists respectively increase and decrease premature responding in the 5-CSRTT ([@bib8]; [@bib36]; [@bib39]). Support for the notion of a balanced interaction between the NAcbS and the NAcbC in the mediation of impulsivity in the 5-CSRTT is the finding that excitotoxic lesions of the NAcbC increased, whereas NAcbS lesions decreased impulsivity produced by the mixed NET/DAT inhibitor [D]{.smallcaps}-amphetamine ([@bib32]).

In contrast to the dissociable effects of intra-NAcb core and shell infusions of ATO and MPH on 5-CSRTT impulsivity, there were no effects on impulsive behavior following local infusions of these drugs into the PrL and IL. This result was rather unexpected considering evidence of: (i) a dysfunctional PFC in ADHD patients ([@bib12]; [@bib44]), (ii) top--down prefrontal control over cognitive and executive functions regulated by catecholamine transmission ([@bib2]; [@bib3]), and (iii) significant increases in premature responding on the 5-CSRTT following selective lesions of the IL cortex ([@bib13]). As NET is abundant within the mPFC, compared with DAT ([@bib25]; [@bib45]), a beneficial effect on impulsivity of intra-mPFC (especially intra-IL) ATO treatment might have been expected. But the results of our experiments clearly indicated that this was not the case. However, other evidence indicates that serotonergic modulation of this region may be an important feature in the context of premature responding on the 5-CSRTT ([@bib34]; [@bib49]). We have also recently reported evidence that the effect of ATO to speed stop-signal reaction time performance (a measure of 'stopping impulsivity\', ([@bib16])) is not mediated by actions within the IL or PL, but instead within the anterior cingulate and orbitofrontal cortices ([@bib5]). One implication is that the multifaceted nature of impulsivity depends on different neural circuitries that are subject to different forms of modulation at both prefrontal cortical and striatal sites. Thus, the beneficial effects of systemically administered ATO may be mediated by effects in multiple neural sites, the precise outcome depending on the specific behavioral demand of the task.

We also investigated whether shared or distinct neurochemical mechanisms modulate premature behavior and locomotor activity, as the latter could in some instances contribute significantly to determine the former. We found identical trends in behavior following MPH and ATO treatment, with MPH increasing, and ATO decreasing, spontaneous locomotor activity. However, for the locomotor-activating actions of MPH, similar but non-identical, intra-NAcb mechanisms were found to control this effect. In fact, both intra-NAcbC (similarly to impulsivity) and intra-NAcbS (differentially from impulsivity) infusions of MPH stimulated locomotor activity. This result is consistent with the well-established effect of increased NAcb DA to enhance behavioral output, producing a state of 'behavioral activation\' ([@bib42]; [@bib46]). By contrast, we demonstrated dissociable mechanisms by which ATO decreases impulsive behavior and locomotor activity. Unlike its effects in the 5-CSRTT, intra-NAcbS NET inhibition by ATO did not alter locomotion but, surprisingly, it was the intra-IL infusions of ATO that produced a significant decrease in locomotor activity, possibly reflecting the known role of the IL cortex in the behavioral suppression of fear and drug-seeking behavior ([@bib38]). These results may indicate that NAcbS NE is specifically recruited in conditions of alertness, also potentially involving the adaptation of behavior over delays to reinforcement (eg, 5-CSRTT). In contrast, the functional importance of an accumbens NE-ergic control over DA transmission in this area seems to be less important when vigilance and attentional demands are low (ie, locomotor activity).

Dysregulated NE and DA neurotransmission have been widely linked with the manifestation of maladaptive impulsive behavior and its related psychopathologies, such as ADHD ([@bib1]; [@bib9]). Human imaging data suggest altered activity in corticostriatal networks in such disorders, and that ATO and MPH exert their therapeutic effects through neuromodulation of these catecholaminergic systems within fronto-striatal circuits ([@bib2]; [@bib3]). Here, we provide substantial evidence for a significant role of the ventral striatum in regulating the expression of impulsive behavior, but found no such evidence for the involvement of prefrontal areas. Thus, the altered prefrontal top--down control shown to be central in some aspects of impulse control disorders may be a consequence of a sub-optimal activity within the NAcb that may derive from a misbalance in NE and DA transmission within its sub-regions. However, as our experiments were carried out in rats not expressing trait-like impulsivity, our data do not exclude the possibility that the PFC is an important site for the beneficial effects of ATO or MPH treatment in patients with impulse control disorders, especially in view of data employing other behavioral test paradigms ([@bib5]; [@bib6]). Rather, it appears that the beneficial actions of ATO are exerted at multiple sites, including striatum and PFC, depending on the precise dimension of impulsivity being measured ([@bib5]; [@bib43]). Finally, we demonstrated that distinct neural mechanisms underlie the modulation of impulsive and locomotor behavior, with the former more obviously depending on DA--NE mechanisms at the level of the ventral striatum. This is an important consideration for dissecting the symptom clusters of hyperactive-impulsive type ADHD, as it shows that these two elements, while often related, may have distinct neurochemical and neural substrates.
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![Schematic representations of injector tips in the (a) NAcbS (open circles), NAcbC (closed circles) and (b) Prl (open circles) and IL cortex (closed circles). Co-ordinates are expressed in mm. Drawings adapted from [@bib37].](npp201253f1){#fig1}

![Mean (±SEM) number of premature responses following intra-NAcbS (a) or intra-NAcbC (b) infusions of ATO and following intra-NAcbS (c) or intra-NAcbC (d) infusions of MPH in rats during performance in the 5-CSRTT. Intra-NAcbS treatment with the selective NET inhibitor ATO significantly decreased premature responding at all doses tested (a) whereas infusions of the mixed DAT/NET inhibitor MPH into the NAcbC produced the opposite effect (d). ^\*^*p*\<0.05 and ^\*\*^*p*\<0.01, compared with vehicle-treated animals; ^\#\#^*p*\<0.01, compared with baseline responding (ITI=5.0 s).](npp201253f2){#fig2}

![Effects of intra-PrL (a) and intra-IL (b) infusions of ATO and of intra-PrL (c) and intra-IL (d) infusions of MPH on premature responses in the 5-CSRTT. Neither compound produced significant effects on premature responding. Data are mean (±SEM) number of premature responses. ^\#\#^*p*\<0.01, compared with baseline responding (ITI=5.0 s).](npp201253f3){#fig3}

![Effects of ATO (a) and MPH (b) infusions into the NAcbC and NAcbS and into the PrL/IL cortex on spontaneous locomotor activity. Data shown are mean (±SEM) photocell beam interruptions. ^\*\*^*p*\<0.01 and ^\*\*\*^*p*\<0.001, compared with vehicle-treated animals.](npp201253f4){#fig4}

###### Brain Stereotaxic Coordinates (Relative to Bregma; mm) for NAcb and mPFC Guide Cannula

  **Region**       **Antero--posterior**   **Lateral**     **Ventral**
  --------------- ----------------------- ------------- ------------------
  mPFC (PrL/IL)            +3.0               ±0.75      1.6 (from dura)
  NAcbS                    +1.7               ±0.75      2.0 (from skull)
  NAcbC                    +1.7               ±1.9       2.2 (from skull)

Drugs were injected through a plastic injector (28-gauge) protruding beyond the cannula tip: 1.5 mm for the PrL, 3.0 mm for the IL, 5.25 mm for the NacbS, and 5.0 mm for the NAcbC.

###### Final Group Sizes with Cannula Placements Histologically Verified

         **Experiment 1**   **Experiment 2**   **Experiment 3**   **Experiment 4**   **Experiment 5**  
  ----- ------------------ ------------------ ------------------ ------------------ ------------------ ---
  ATO           5                  9                  8                  9                  8           8
  MPH           5                  8                  8                  9                  8           8

###### Summary of the Effects of Intra-NAcbS and Intra-NAcbC Infusions of ATO and MPH on 5-CSRTT Performance

                            **ATO**        **MPH**                                                                                     
  ------------------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------- --------------
  *NAcbS*                                                                                                                              
   Accuracy (%)             87.3±0.9       89.2±1.1       87.6±2.9       89.6±1.1       87.5±2.5       90.7±1.0       88.3±2.0         84.4±1.5
   Omissions (%)            5.2±1.1        4.6±2.0        5.0±2.3        8.2±2.9        8.2±3.4        5.4±2.0        6.0±2.3          11.0±1.9
   Perseverative NPs        35.4±4.2       46.4±8.5       45.8±11.1      47.8±13.3      43.6±11.8      52.0±16.5      53.4±16.5        81.0±14.5
   Correct latency (ms)     513.1±29.0     519.7±32.3     497.5±32.9     550.1±46.2     480.3±19.2     444.3±19.5     432.7±17.4^\*^   462.7±13.2
   Incorrect latency (ms)   1297.5±174.3   1118.2±209.3   1350.1±329.7   1665.3±262.1   1221.0±179.4   995.6±197.3    1046.3±120.1     1192.2±187.9
   Collect latency (ms)     1728.2±229.0   2134.2±494.9   2022.9±487.0   1968.9±342.5   1642.7±226.3   1576.6±118.1   2028.3±330.9     1675.2±135.4
                                                                                                                                        
  *NAcbC*                                                                                                                              
   Accuracy (%)             79.1±1.6       ---            80.2±2.2       76.7±3.9       79.2±3.8       78.2±3.7       69.9±8.2         74.7±5.2
   Omissions (%)            9.8±2.1        ---            9.2±1.7        11.3±1.7       7.6±1.4        13.3±5.9       20.7±7.1         20.3±3.3
   Perseverative NPs        76.9±10.8      ---            63.7±6.1       85.7±17.7      55.3±6.9       61.3±8.9       58.4±7.7         67.6±9.0
   Correct latency (ms)     576.5±35.2     ---            633.1±60.4     672.3±78.3     575.9±37.5     647.6±43.8     609.1±43.7       608.0±60.4
   Incorrect latency (ms)   1174.3±94.3    ---            1337.0±130.2   1503.2±177.4   1430.1±175.9   1458.0±137.5   1558.0±148.5     1937.4±208.2
   Collect latency (ms)     1552.7±88.2    ---            1545.2±108.3   1612.8±104.6   1701.0±69.7    1770.5±97.4    1639.5±54.3      1591.7±63.7

^\*^*p*\<0.05, compared with vehicle-treated animals.

Data are shown as mean (± SEM).

###### Summary of the Effects of Intra-PrL and Intra-IL Infusions of ATO and MPH on 5-CSRTT Performance

                            **ATO**        **MPH**                                                     
  ------------------------- -------------- -------------- -------------- -------------- -------------- --------------
  *PrL*                                                                                                
   Accuracy (%)             87.0±1.3       90.2±2.2       87.8±1.9       83.1±3.8       82.1±2.8       81.3±3.2
   Omissions (%)            3.3±1.0        3.6±1.1        3.9±0.7        4.6±0.9        4.9±0.8        5.9±2.3
   Perseverative NPs        36.3±8.1       37.6±4.8       52.3±9.2       54.6±10.8      50.1±9.0       61.3±10.5
   Correct latency (ms)     461.9±17.2     496.7±26.3     480.1±17.8     468.7±7.1      460.8±12.7     467.3±28.9
   Incorrect latency (ms)   1039.1±75.9    1130.3±249.2   1258.6±219.9   1151.5±169.7   1083.7±162.1   1363.7±178.9
   Collect latency (ms)     1397.4±70.4    1525.8±151.0   1558.6±93.4    1454.9±107.2   1427.1±61.8    1807.3±395.4
                                                                                                        
  *IL*                                                                                                 
   Accuracy (%)             88.0±1.9       86.3±2.2       88.3±1.8       86.2±2.0       87.0±3.0       87.2±2.7
   Omissions (%)            5.8±1.2        5.7±1.8        4.3±0.5        5.6±1.0        4.1±1.1        2.9±0.9^\*^
   Perseverative NPs        41.0±10.1      51.5±13.9      46.2±7.4       59.9±9.3       56.3±6.7       55.1±8.2
   Correct latency (ms)     429.0±17.4     488.8±39.1     456.7±28.4     486.2±12.1     488.9±20.7     481.2±18.6
   Incorrect latency (ms)   1367.0±233.2   1246.1±154.5   1180.7±207.4   1173.5±206.1   1339.2±145.5   1077.6±199.2
   Collect latency (ms)     1447.4±40.1    1464.9±117.5   1428.5±82.9    1535.1±82.1    1554.9±65.6    1569.9±97.1

^\*^*p*\<0.05, compared with vehicle-treated animals.

Data are shown as mean (± SEM).
